Effect of vitamin D receptor activators on serum Klotho levels in 3b–4 stages chronic кidney disease patients: a prospective randomized study
- Authors: Milovanova L.Y.1, Beketov V.D.1, Milovanova S.Y.1, Taranova M.V.1, Kozlov V.V.1, Pasechnik A.I.2, Reshetnikov V.A.1, Androsova T.V.1, Kalashnikov M.V.1
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Lomonosov Moscow State University
- Issue: Vol 93, No 6 (2021)
- Pages: 679-684
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/75948
- DOI: https://doi.org/10.26442/00403660.2021.06.000854
- ID: 75948
Cite item
Full Text
Abstract
Background. High risk of cardiovascular events is among leading problems in chronic kidney disease (CKD). Serum Klotho is supposed to be cardio- and nephroprotective; modification of its levels may be important in CKD.
Aim. To evaluate the impact of vitamin D receptor activators (VDRA) on Klotho serum levels in CKD 3b–4 stages patients.
Materials and methods. Study included 90 CKD 3b–4 stages patients who had elevated serum levels of parathyroid hormone (PTH). From them, 47 patients (group 1) started to treat with the selective VDRA (zemplar 1 mcg/day), and 43 patients (group 2) started to treat with non-selective VDRA (alfacalcidol 0.25 mcg/day). At baseline and after 12 months we conducted routine examination, serum Klotho measurement, and broad cardiovascular examination.
Results. The patients who managed to maintain a target serum PTH level, had higher Klotho serum level (p=0.037) at the end of the study. Patients who used selective VDRA significantly more often reached the target PTH level (p=0.032), had higher serum Klotho levels (p=0.037), and glomerular filtration rate (eGFR) level (p=0.048) than patients who used non-selective VDRA. In addition, patients treated with alfacalcidol more than 6 months, more often had hypercalcemia (p=0.047) and hyperphosphatemia (p=0.035). Group 2 showed higher: pulse wave velocity (p=0.051), left ventricular myocardial mass index (p=0.033), and more advanced heart valve calcification (p=0.038).
Conclusion. Successful parathyroid hormone level control with vitamin D receptor activators was associated with higher serum Klotho, selective agents having shown greater effect. Long-term treatment with selective vitamin D receptor activators may contribute to cardiovascular calcification prevention by modifying Klotho levels.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Ludmila Yu. Milovanova
Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: Ludm.milovanova@gmail.com
ORCID iD: 0000-0002-5599-0350
д-р мед. наук, проф. каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
Russian Federation, MoscowVladimir D. Beketov
Sechenov First Moscow State Medical University (Sechenov University)
Email: Ludm.milovanova@gmail.com
ORCID iD: 0000-0002-6377-0630
канд. мед. наук, доц. каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
Russian Federation, MoscowSvetlana Yu. Milovanova
Sechenov First Moscow State Medical University (Sechenov University)
Email: Ludm.milovanova@gmail.com
ORCID iD: 0000-0002-2687-6161
д-р мед. наук, проф. каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
Russian Federation, MoscowMarina V. Taranova
Sechenov First Moscow State Medical University (Sechenov University)
Email: Ludm.milovanova@gmail.com
ORCID iD: 0000-0002-7363-6195
канд. мед. наук, доц. каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
Russian Federation, MoscowVasilii V. Kozlov
Sechenov First Moscow State Medical University (Sechenov University)
Email: Ludm.milovanova@gmail.com
ORCID iD: 0000-0002-2389-3820
доц. каф. общественного здоровья и организации здравоохранения ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
Russian Federation, MoscowAnastasiia I. Pasechnik
Lomonosov Moscow State University
Email: Ludm.milovanova@gmail.com
ORCID iD: 0000-0002-7544-3696
ординатор каф. внутренних болезней фак-та фундаментальной медицины ФГБОУ ВО «МГУ им. М.В. Ломоносова»
Russian Federation, MoscowVladimir A. Reshetnikov
Sechenov First Moscow State Medical University (Sechenov University)
Email: Ludm.milovanova@gmail.com
ORCID iD: 0000-0002-2987-7995
д-р мед. наук, проф. каф. общественного здоровья и организации здравоохранения ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
Russian Federation, MoscowTatiana V. Androsova
Sechenov First Moscow State Medical University (Sechenov University)
Email: Ludm.milovanova@gmail.com
ORCID iD: 0000-0002-9951-126X
канд. мед. наук, доц. каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
Russian Federation, MoscowMikhail V. Kalashnikov
Sechenov First Moscow State Medical University (Sechenov University)
Email: Ludm.milovanova@gmail.com
ORCID iD: 0000-0003-4828-6338
аспирант каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
Russian Federation, MoscowReferences
- Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305. doi: 10.1056/NEJMoa041031
- Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80(12):1258-70. doi: 10.1038/ki.2011.368
- Grabner A, Faul C. The Role of FGF23 and Klotho in Uremic Cardiomyopathy. Curr Opin Nephrol Hypertens. 2016;25:314-24. doi: 10.1097/MNH.0000000000000231..5
- Neyra JA, Hu MC. Potential application of Klotho in human chronic kidney disease. Bone. 2017;100:41-9. doi: 10.1016/j.bone.2017.01.017
- Xie J, Yoon J, An SW, et al. Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate. J Am Soc Nephrol. 2015;26:1150-60. doi: 10.1681/ASN.2014040325
- Kuro-o M. Klotho and chronic kidney disease – Whats new? Nephrol Dial Transplant. 2009;24(6):1705-8. doi: 10.1093/ndt/gfp069
- Carracedo J, Alique M, Vida C, et al. Mechanisms of Cardiovascular Disorders in Patients With Chronic Kidney Disease: A Process Related to Accelerated Senescence. Front Cell Dev Biol. 2020;8:185. doi: 10.3389/fcell.2020.00185
- Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and Klotho: Physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol. 2013;75:503-33. doi: 10.1146/annurev-physiol-030212-183727
- Seifert ME, De Las Fuentes L, Ginsberg C, et al. Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease. Am J Nephrol. 2014;39:392-9. doi: 10.1159/000362251
- Memmos E, Sarafidis P, Pateinakis P, et al. Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis. BMC Nephrol. 2019;11:217. doi: 10.1186/s12882-019-1391-1
- Kim HJ, Kang E, Oh YK, et al. The association between soluble Klotho and cardiovascular parameters in chronic kidney disease: Results from the KNOW-CKD study. BMC Nephrol. 2018;5:51. doi: 10.1186/s12882-018-0851-3
- Li F, Yao Q, Ao L, et al. Klotho suppresses high phosphate-induced osteogenic responses in human aortic valve interstitial cells through inhibition of Sox9. J Mol Med. 2017;95:739-51. doi: 10.1007/s00109-017-1527-3
- Hu MC, Shi M, Gillings N, et al. Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy. Kidney Int. 2017;91:1104-14. doi: 10.1016/j.kint.2016.10.034
- Levin A, Stevens PE, Bilous RW, et al. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO. 2012 clinical practice guide-line for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1-150. doi: 10.1038/kisup.2012.73
- Mancia G, Fagard R, Narkiewicz K, et al. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219. doi: 10.1093/eurheartj/eht151
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evolution, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;76:S1-130
- Ермоленко В.М., Волгина Г.В., Добронравов В.А., и др. Национальные рекомендации по минеральным и костным нарушениям при хронической болезни почек. Российское диализное общество (май 2010 г.). Нефрология и диализ. 2011;13(1):33-51 [Ermolenko VM, Volgina GV, Dobronravov VA, et al. National recommendations on mineral and bone disorders in chronic kidney disease. Russian Dialysis Society (May 2010). Nephrologia i dialis. 2011;13(1):33-51 (in Russian)]
- Lau WL, LeafEM, Hu MC, et al. Vitamin D receptor agonists increase Klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int. 2012;82(12):1261-70. doi: 10.1038/ki.2012.322
- Naves-Díaz M, Alvarez-Hernández D, Passlick-Deetjen J, et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int. 2008;74:1070-8. doi: 10.1038/ki.2008.343
- Becker LE, Koleganova N, Piecha G, et al. Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice. Am J Physiol Renal Physiol. 2011;300:F772-82. doi: 10.1152/ajprenal.00042.2010
- Lopez I, Mendoza FJ, Aguilera-Tejero E, et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int. 2008;73:300-7. doi: 10.1038/sj.ki.5002675
- Cardús A, Panizo S, Parisi E, et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res. 2007;22:860-6. doi: 10.1359/jbmr.070305
- Jono S, Nishizawa Y, Shioi A, et al. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation. 1998;98:1302-6. doi: 10.1161/01.cir.98.13.1302
- Li X, Speer MY, Yang H, et al. Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin. Arterioscler Thromb Vasc Biol. 2010;30:321-6. doi: 10.1161/ATVBAHA.109.196576
- Wu-Wong JR, Noonan W, Ma J, et al. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther. 2006;318:90-8. doi: 10.1124/jpet.106.101261
- Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med. 2002;139:279-84. doi: 10.1111/j.1523-1755.2002.kid573.x
- Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446-56. doi: 10.1056/NEJMoa022536
- Mathew S, Lund RJ, Chaudhary LR, et al. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol. 2008;19:1509-19. doi: 10.1681/ASN
- Mizobuchi M, Finch JL, Martin DR, et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. 2007;72:709-15. doi: 10.1038/sj.ki.5002406
- Kumar V, Yadav AK, Singhal M, et al. Vascular function and cholecalciferol supplementation in CKD: A self-controlled case series. J Steroid Biochem Mol Biol. 2018;180:19-22. doi: 10.1016/j.jsbmb.2018.01.001
- Chitalia N, Ismail T, Tooth L, et al. Impact of Vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients. PLoS ONE. 2014;9:e91363. doi: 10.1371/journal.pone.0091363
- Lundwall K, Jacobson SH, Jörneskog G, Spaak J. Treating endothelial dysfunction with Vitamin D in chronic kidney disease: A metaanalysis. BMC Nephrol. 2018;19:247. doi: 10.1186/s12882-018-1042-y
- Chen S, Law CS, Grigsby CL, et al. Cardiomyocyte-specific deletion of the Vitamin D receptor gene results in cardiac hypertrophy. Circulation. 2011;124:1838-47. doi: 10.1161/CIRCULATIONAHA.111.032680
- Olejnik A, Franczak A, Krzywonos-Zawadzka A, et al. The Biological Role of Klotho Protein in the Development of Cardiovascular Diseases. Biomed Res Int. 2018;2018:5171945. doi: 10.1155/2018/5171945
- Buchanan S, Combet E, Stenvinkel P, Shiels PG. Klotho, Aging, and the Failing Kidney. Front Endocrinol (Lausanne). 2020;11:560. doi: 10.3389/fendo.2020.00560
- Weishaar RE, Simpson RU. Vitamin D3 and cardiovascular function in rats. J Clin Investig. 1987;79:1706-12. doi: 10.1172/JCI113010
- Gluba-Brzózka A, Franczyk B, Ciałkowska-Rysz A, et al. Impact of Vitamin D on the Cardiovascular System in Advanced Chronic Kidney Disease (CKD) and Dialysis Patients Nutrients. 2018;10(6):709. doi: 10.3390/nu10060709
- Levin A, Li YC. Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease? Kidney Int. 2005;68:1973-81. doi: 10.1111/j.1523-1755.2005.00651.x
- Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Investig. 2002;110:229-38. doi: 10.1172/JCI0215219
- Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem. 2003;88:327-31. doi: 10.1002/jcb.10343
- Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005;288:E125-32. doi: 10.1152/ajpendo.00224.2004
- Zhou L, Mo H, Miao J, et al. Klotho Ameliorates Kidney Injury and Fibrosis and Normalizes Blood Pressure by Targeting the Renin-Angiotensin System. Am J Pathol. 2015;185(12):3211-23. doi: 10.1016/j.ajpath.2015.08.004
Supplementary files
![](/img/style/loading.gif)